Foghorn’s Second Quarter 2026 Financial and Corporate Update Read more

OUR PIPELINE

We believe that our potential therapies will have the ability to transform the lives of people with a wide spectrum of diseases, including many types of cancer. Through our pipeline of proprietary enzymatic inhibitors and targeted protein degraders, we are building the next wave of precision therapies.

  • Oncology
  • I & I
Program Disease Area Preclinical Phase 1 Next Clinical Milestone
Selective SMARCA2
Inhibitor FHD-909*		 Foghorn Therapeutics and Loxo Oncology at Lilly SMARCA4-mutant cancers (e.g., NSCLC)

Phase 1a Monotherapy Data; Dose Expansion Decision
Selective EP300 Degrader Heme malignancies (MM and DLBCL) and prostate cancer

IND Targeted in 2027
Selective CBP Degrader ER+ breast cancer

-
Selective ARID1B Degrader ARID1A-mutant cancers (e.g., endometrial, gastric, bladder, NSCLC)

-
Novel Small Molecule Undisclosed

IND Targeted in 2027

Other Collaboration Programs

  • Selective SMARCA2 Degrader
  • Undisclosed Inhibitor**
  • 3 Discovery Programs

Ongoing Initiatives

  • Induced Proximity
  • RIPTACs
  • Molecular Glues

*LY4050784, 50/50 U.S. economic split, ex-U.S. royalties. **Pending Lilly decision to proceed, 50/50 U.S. economic split, ex-U.S. royalties.
SMARCA2 = BRM
DLBCL: Diffuse Large B-Cell Lymphoma; ER+: Estrogen Receptor-positive; I&I: Immunology and Inflammation; MM: Multiple Myeloma; NSCLC: Non-Small Cell Lung cancer

  • Oncology
  • I & I
Selective SMARCA2
Inhibitor FHD-909*
SMARCA4-mutant cancers (e.g., NSCLC)
Foghorn Therapeutics and Loxo Oncology at Lilly

Phase 1

Next Clinical Milestone:
Phase 1a Monotherapy Data; Dose Expansion Decision

Selective EP300 Degrader
Heme malignancies (MM and DLBCL) and prostate cancer

Preclinical

Next Clinical Milestone:
IND Targeted in 2027

Selective CBP Degrader
ER+ breast cancer

Preclinical
Selective ARID1B Degrader
ARID1A-mutant cancers (e.g., endometrial, gastric, bladder, NSCLC)

Preclinical
Novel Small Molecule
Undisclosed

Preclinical

Next Clinical Milestone:
IND Targeted in 2027

Other Collaboration Programs

  • Selective SMARCA2 Degrader
  • Undisclosed Inhibitor**
  • 3 Discovery Programs

Ongoing Initiatives

  • Induced Proximity
  • RIPTACs
  • Molecular Glues

*LY4050784, 50/50 U.S. economic split, ex-U.S. royalties. **Pending Lilly decision to proceed, 50/50 U.S. economic split, ex-U.S. royalties.
SMARCA2 = BRM
DLBCL: Diffuse Large B-Cell Lymphoma; ER+: Estrogen Receptor-positive; I&I: Immunology and Inflammation; MM: Multiple Myeloma; NSCLC: Non-Small Cell Lung cancer

OUR CANDIDATE IN THE CLINIC

FHD-909

FHD-909 (LY4050784) is a potent, first-in-class, allosteric and orally available small molecule that selectively inhibits the ATPase activity of SMARCA2 (BRM) over its closely related paralog SMARCA4 (BRG1), two proteins that are the catalytic engines across all forms of the BAF complex, one of the key regulators of the chromatin regulatory system. In preclinical studies, tumors with mutations in SMARCA4 rely on SMARCA2 for BAF function. FHD-909 has shown significant anti-tumor activity across multiple SMARCA4 mutant lung tumor models.

Target & Modality

SMARCA2 ATPase

Potent, selective, allosteric, small molecule, oral enzymatic inhibitor

Primary Indication

Non-Small Cell Lung Cancer

Genetic Dependency

SMARCA4-mutated cancers

OUR COLLABORATOR

Our collaboration with Lilly includes a co-development and co-commercialization agreement on the selective SMARCA2 oncology program (a selective inhibitor and a selective degrader) and an additional undisclosed oncology target. The partnership also includes three additional discovery programs using Foghorn’s proprietary Gene Traffic Control® platform.

Investor Resources

View investor portal

Find out more about our company, accomplishments, news, and latest events.